08:06 AM EDT, 07/08/2024 (MT Newswires) -- Amarin ( AMRN ) said Monday China's National Medical Products Administration has granted an approval to its commercial partner EddingPharm for the heart drug Vascepa.

The approval was granted for Vascepa to lower the risk of cardiovascular events as an adjunct to statin therapy in adult patients with elevated and high triglycerides and established cardiovascular disease or diabetes mellitus with at least two additional cardiovascular risk factors, combined with hypertriglyceridemia.

Amarin ( AMRN ) said its partner now is trying to get Vascepa included on the National Reimbursement Drug Listing and to include the Cardiovascular Risk Reduction indication on the product's commercial launch in China.

Price: 0.7705, Change: +0.03, Percent Change: +4.62